SCHEMBL22524317

SCHEMBL22524317

CCCCNc1ncnc2[nH]c(-c3ccnn3C)cc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.56
▸ AURKB Q96GD4 1/20 0.56
▸ INCENP Q9NQS7 1/20 0.56
▸ ALDH1A1 P00352 3/20 0.42
▸ HPGD P15428 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ NFKB1 P19838 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ NFKB2 Q00653 2/20 0.42
▸ RELA Q04206 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ ALOX12 P18054 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ S1PR2 O95136 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22524218 0.77 KIT (0.48) AURKBINCENPALDH1A1HPGDSMN1; SMN2
SCHEMBL22524220 0.77 EGFR (0.57) EGFRSMN1; SMN2LMNAS1PR2NPSR1
SCHEMBL22524205 0.73 SMN1; SMN2 (0.47) ALDH1A1HPGDSMN1; SMN2KDM4ENPC1
SCHEMBL22524221 0.72 SMN1; SMN2 (0.46) ALDH1A1HPGDSMN1; SMN2KDM4ENPC1
SCHEMBL22524214 0.69 SMN1; SMN2 (0.43) ALDH1A1HPGDSMN1; SMN2KDM4ENPC1
SCHEMBL24453850 0.69 CSF1R (0.48) ALDH1A1HPGDSMN1; SMN2KDM4ENPC1
SCHEMBL22524350 0.69 CSF1R (0.56) ALDH1A1HPGDSMN1; SMN2KDM4ENPC1
SCHEMBL22524215 0.68 SMN1; SMN2 (0.41) EGFRALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL25786355 0.66 AURKB (0.42) EGFRAURKBINCENPALDH1A1COMT
SCHEMBL22524216 0.65 SMN1; SMN2 (0.39) EGFRALDH1A1HPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220162215-A1 COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE MITOKININ INC (US) 2022-05-26 — — US disclosed
WO-2020206363-A1 COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE MITOKININ,INC. (US) 2020-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162215-A1 COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE NLN, PINK1, NME4 EGFR 4203/4885AURKB 1222/4885INCENP 2165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback